Courtney Flaherty

A novel all-antibody therapy shows remarkable efficacy and safety in elderly patients with newly diagnosed multiple myeloma, achieving high response rates and MRD negativity.

A RAD51-based assessment identifies HER2-negative breast cancer patients likely to benefit from olaparib, enhancing treatment selection and outcomes.

Elacestrant shows promising results in combination therapies for ER-positive, HER2-negative metastatic breast cancer, enhancing progression-free survival and maintaining safety.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

KLN-1010 shows promising MRD-negative responses in relapsed/refractory multiple myeloma patients, highlighting its potential as a safe, off-the-shelf CAR T therapy.

A new triplet therapy combining tagraxofusp, azacitidine, and venetoclax shows promising response rates and transplant potential for BPDCN patients.

Firmonertinib shows significant antitumor activity in EGFR PACC-mutated NSCLC, with promising results in CNS penetration and manageable safety profiles.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A.

In patients with advanced ESCC treated with first-line tislelizumab plus chemotherapy, deeper responses and longer time to maximum response were linked to improved overall survival.

Updated phase 2 trial data presented at the 2024 ASH Annual Meeting show that the novel bicistronic CD19/CD22-directed CAR T-cell therapy is safe, durable, and highly effective in children with relapsed/refractory B-ALL.

Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.

A new allogeneic CAR T-cell therapy, P-BCMA-ALLO1, has shown promising results in treating heavily pretreated patients with relapsed/refractory multiple myeloma.

In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.

Lurbinectedin and irinotecan in the second line delivered a favorable risk/benefit profile and high, durable response rates in patients with high risk factors in small cell lung cancer.

The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

Topline findings from the KICKSTART study showed that tomivosertib led to modest activity in non-small cell lung cancer (NSCLC).

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.

In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.

Acalabrutinib added to axicabtagene ciloleucel treatment was well-tolerated in patients with relapsed/refractory B-cell lymphoma.

The combination of olaparib and abiraterone acetate resulted in a postponement of disease progression and enhanced outcomes for individuals with mutations in BRCA, ATM, and CDK12 in metastatic castration-resistant prostate cancer.

The majority of patients with relapsed chronic lymphocytic leukemia treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation.

Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.